Details for New Drug Application (NDA): 204679

NDA 204679 describes ROCURONIUM BROMIDE, which is a drug marketed by Caplin, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hospira, Meitheal, Mylan Institutional, Norvium Bioscience, Piramal Critical, Prinston Inc, Sagent Pharms Inc, Sandoz, Shandong, Steriscience, Tamarang, Teva Pharms, and West Ward Pharm Corp, and is included in eighteen NDAs. It is available from twenty-three suppliers. Additional details are available on the ROCURONIUM BROMIDE profile page.

The generic ingredient in ROCURONIUM BROMIDE is rocuronium bromide. There are eleven drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the rocuronium bromide profile page.

Summary for 204679

Tradename:	ROCURONIUM BROMIDE
Applicant:	West Ward Pharm Corp
Ingredient:	rocuronium bromide
Patents:	0

Pharmacology for NDA: 204679

Physiological Effect

Neuromuscular Nondepolarizing Blockade

Suppliers and Packaging for NDA: 204679

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ROCURONIUM BROMIDE	rocuronium bromide	INJECTABLE;INJECTION	204679	ANDA	Hikma Pharmaceuticals USA Inc.	0143-9250	0143-9250-10	10 VIAL in 1 BOX (0143-9250-10) / 5 mL in 1 VIAL (0143-9250-01)
ROCURONIUM BROMIDE	rocuronium bromide	INJECTABLE;INJECTION	204679	ANDA	Hikma Pharmaceuticals USA Inc.	0143-9251	0143-9251-10	10 VIAL in 1 BOX (0143-9251-10) / 10 mL in 1 VIAL (0143-9251-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	50MG/5ML (10MG/ML)
Approval Date:	Feb 28, 2017	TE:	AP	RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	100MG/10ML (10MG/ML)
Approval Date:	Feb 28, 2017	TE:	AP	RLD:	No

Complete Access Available with Subscription